Verona Pharma (VRNA)

• Market cap: $9.21B
• 1 day: 0.03%
• 5 days: 0.08%
• 1 month: 1.18%
• 3 months: 15.06%
• 6 months: 57.44%
• Year to date: 120.81%
• 1 year: 254.88%
• 5 years: 1,409.65%
• 10 years: 688.37%
• Sector: Healthcare
• Industry: Biotechnology

About: Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

Employees: 209

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

112% more first-time investments, than exits

New positions opened: 70 | Existing positions closed: 33

77.78% more ownership

Funds ownership: 11.41% [Q1] → 89.2% (+77.78%) [Q2]

57% more capital invested

Capital invested by funds: $4.58B [Q1] → $7.18B (+$2.6B) [Q2]

13% more funds holding

Funds holding: 258 [Q1] → 291 (+33) [Q2]

4% more funds holding in top 10

Funds holding in top 10: 28 [Q1] → 29 (+1) [Q2]

27% less repeat investments, than reductions

Existing positions increased: 80 | Existing positions reduced: 109

69% less call options, than puts

Call options by funds: $102M | Put options by funds: $328M

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $107
• Avg. target: $125
• High target: $170

7 analyst ratings

• positive: 3 43%
• neutral: 4 57%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju	$107	Neutral Downgraded	14 Jul 2025
Wells Fargo Tiago Fauth	$107	Equal-Weight Downgraded	10 Jul 2025
Jefferies Suji Jeong	$107	Hold Downgraded	9 Jul 2025
Canaccord Genuity Edward Nash	$107	Hold Downgraded	9 Jul 2025
Wolfe Research Andy Chen	$170	Outperform Initiated	1 Jul 2025